Trial Profile

A Multicenter, Single-arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 May 2026 According to a Novartis media release, data from this study will be presented at the European Hematology Association (EHA) 2026 Congress.
12 Jun 2025 According to a Novartis media release, company will present data from this study at the European Hematology Association (EHA) Congress 2025.
14 Apr 2025 According to a Novartis media release, based on data from this and APPLY-PNH studies Health Canada approved Fabhalta (iptacopan capsules), first oral treatment for adult patients with PNH

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com